Preethi Srinivasan
Overview
Explore the profile of Preethi Srinivasan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
3138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srinivasan P, Karah H, Srinivasan S
Cult Health Sex
. 2024 Sep;
:1-15.
PMID: 39289884
Disabled women with significant impairments (DWSI) are not adequately recognised within feminist disability studies. They face stigma, carnal taboos, and systemic exclusion from economies of desire and sexuality. Their voices...
2.
Li A, He B, Karagiannis D, Li Y, Jiang H, Srinivasan P, et al.
Proc Natl Acad Sci U S A
. 2023 Sep;
120(38):e2302489120.
PMID: 37695911
Loss of estrogen receptor (ER) pathway activity promotes breast cancer progression, yet how this occurs remains poorly understood. Here, we show that serine starvation, a metabolic stress often found in...
3.
Franch-Exposito S, Mehine M, Ptashkin R, Bolton K, Bandlamudi C, Srinivasan P, et al.
JCO Precis Oncol
. 2023 Aug;
7:e2300070.
PMID: 37561983
Purpose: Clonal hematopoiesis (CH), the expansion of clones in the hematopoietic system, has been linked to different internal and external features such as aging, genetic ancestry, smoking, and oncologic treatment....
4.
Pietzak E, Whiting K, Srinivasan P, Bandlamudi C, Khurram A, Joseph V, et al.
Clin Cancer Res
. 2022 Jul;
28(19):4267-4277.
PMID: 35833951
Purpose: Identification of inherited germline variants can guide personalized cancer screening, prevention, and treatment. Pathogenic and likely pathogenic (P/LP) germline variants in cancer predisposition genes are frequent among patients with...
5.
Mukherjee S, Bandlamudi C, Hellmann M, Kemel Y, Drill E, Rizvi H, et al.
Cancer Epidemiol Biomarkers Prev
. 2022 Apr;
31(7):1450-1459.
PMID: 35477182
Background: The genetic factors that modulate risk for developing lung cancer have not been fully defined. Here, we sought to determine the prevalence and clinical significance of germline pathogenic/likely pathogenic...
6.
Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan S, Richards A, et al.
Nat Genet
. 2021 Nov;
53(11):1577-1585.
PMID: 34741162
Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152 prospectively sequenced patients with cancer, we identified pathogenic germline...
7.
Cercek A, Chatila W, Yaeger R, Walch H, Fernandes G, Krishnan A, et al.
J Natl Cancer Inst
. 2021 Aug;
113(12):1683-1692.
PMID: 34405229
Background: The causative factors for the recent increase in early-onset colorectal cancer (EO-CRC) incidence are unknown. We sought to determine if early-onset disease is clinically or genomically distinct from average-onset...
8.
Salo-Mullen E, Maio A, Mukherjee S, Bandlamudi C, Shia J, Kemel Y, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250384
Materials And Methods: Patients with pan-cancer (n = 11,081) underwent matched tumor-normal sequencing with consent for germline analysis. Medical records and tumors were reviewed and analyzed. Prevalence of PVs was...
9.
Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, et al.
Nat Commun
. 2021 Jun;
12(1):3770.
PMID: 34145282
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA...
10.
Tsui D, Cheng M, Shady M, Yang J, Stephens D, Won H, et al.
Genome Med
. 2021 Jun;
13(1):96.
PMID: 34059130
Background: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay...